With AstraZeneca’s US$38.8 billion bid for Alexion Pharmaceuticals, global merger and acquisition activity will top US$1 trillion for the second straight quarter, Refinitiv says.
The proposed pharma mega-merger would be the seventh-largest deal of the year, which has included 111 deals valued in excess of US$5 billion.
This represents an increase in mega-merger activity from 2019, and is the fourth-highest annual total on record, Refinitiv said.
Last year, there were 97 deals that topped the US$5-billion mark.
Since July, there has been US$2.1 trillion in deal activity — which would be the second-highest total on record for the second half of a year, Refinitiv said.